ZA201708439B - Vegfr-2 targeting dna vaccine for combination therapy - Google Patents

Vegfr-2 targeting dna vaccine for combination therapy

Info

Publication number
ZA201708439B
ZA201708439B ZA2017/08439A ZA201708439A ZA201708439B ZA 201708439 B ZA201708439 B ZA 201708439B ZA 2017/08439 A ZA2017/08439 A ZA 2017/08439A ZA 201708439 A ZA201708439 A ZA 201708439A ZA 201708439 B ZA201708439 B ZA 201708439B
Authority
ZA
South Africa
Prior art keywords
vegfr
combination therapy
dna vaccine
targeting dna
targeting
Prior art date
Application number
ZA2017/08439A
Other languages
English (en)
Inventor
Heinz Lubenau
Original Assignee
Vaximm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Ag filed Critical Vaximm Ag
Publication of ZA201708439B publication Critical patent/ZA201708439B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ZA2017/08439A 2015-06-18 2017-12-12 Vegfr-2 targeting dna vaccine for combination therapy ZA201708439B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15001803 2015-06-18
PCT/EP2016/001004 WO2016202459A1 (en) 2015-06-18 2016-06-16 Vegfr-2 targeting dna vaccine for combination therapy

Publications (1)

Publication Number Publication Date
ZA201708439B true ZA201708439B (en) 2021-05-26

Family

ID=53476620

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/08439A ZA201708439B (en) 2015-06-18 2017-12-12 Vegfr-2 targeting dna vaccine for combination therapy

Country Status (19)

Country Link
US (2) US10905752B2 (cg-RX-API-DMAC7.html)
EP (2) EP3626262B1 (cg-RX-API-DMAC7.html)
JP (1) JP6947649B2 (cg-RX-API-DMAC7.html)
KR (2) KR20180037948A (cg-RX-API-DMAC7.html)
CN (1) CN107995868B (cg-RX-API-DMAC7.html)
AU (1) AU2016278588B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017027378A2 (cg-RX-API-DMAC7.html)
CA (1) CA2989247C (cg-RX-API-DMAC7.html)
DK (1) DK3310379T3 (cg-RX-API-DMAC7.html)
ES (2) ES2760699T3 (cg-RX-API-DMAC7.html)
HU (1) HUE046631T2 (cg-RX-API-DMAC7.html)
IL (1) IL256076A (cg-RX-API-DMAC7.html)
LT (1) LT3310379T (cg-RX-API-DMAC7.html)
MX (1) MX2017016183A (cg-RX-API-DMAC7.html)
PL (2) PL3310379T3 (cg-RX-API-DMAC7.html)
RU (1) RU2018101722A (cg-RX-API-DMAC7.html)
SI (1) SI3310379T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016202459A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708439B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019112977A (ru) * 2016-11-04 2020-12-04 Факсимм Аг Днк-вакцина, нацеленная на wt1, для комбинированной терапии
CA3050833A1 (en) * 2017-02-17 2018-08-23 Vaximm Ag Novel vegfr-2 targeting immunotherapy approach
JP7247097B2 (ja) * 2017-03-17 2023-03-28 バクシム アクチェンゲゼルシャフト がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン
AU2019334131B2 (en) * 2018-09-05 2025-12-18 NEC Oncolmmunity AS Neoantigen targeting DNA vaccine for combination therapy
WO2021144254A1 (en) 2020-01-13 2021-07-22 Vaximm Ag Salmonella-based dna vaccines in combination with an antibiotic
EP3922255A1 (en) * 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094410B2 (en) 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
NO337687B1 (no) 2011-07-08 2016-06-06 Norsk Elektro Optikk As Hyperspektralt kamera og metode for å ta opp hyperspektrale data
MX355134B (es) * 2011-12-22 2018-04-06 Vaximm Ag Metodo para producir cepas atenuadas de salmonella con alto rendimiento.
US9415098B2 (en) * 2012-07-05 2016-08-16 Vaximm Ag DNA vaccine for use in pancreatic cancer patients
EP2897620B1 (en) * 2012-09-21 2020-07-22 Intensity Therapeutics, Inc Method of treating cancer
MX385338B (es) * 2013-02-22 2025-03-18 CureVac SE Combinación de vacunación e inhibición de la trayectoria pd-1.
JP6416877B2 (ja) * 2013-04-25 2018-10-31 バクシム アクチェンゲゼルシャフト ウィルムス腫瘍遺伝子ｗｔ１を標的とする癌免疫療法用のサルモネラベースのベクター
JP6662787B2 (ja) * 2013-12-18 2020-03-11 バキシム ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌免疫療法のための新規ｍｓｌｎ標的化ｄｎａワクチン
CA3050833A1 (en) * 2017-02-17 2018-08-23 Vaximm Ag Novel vegfr-2 targeting immunotherapy approach
JP7247097B2 (ja) * 2017-03-17 2023-03-28 バクシム アクチェンゲゼルシャフト がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン

Also Published As

Publication number Publication date
CN107995868A (zh) 2018-05-04
US20210077605A1 (en) 2021-03-18
EP3626262B1 (en) 2024-10-23
EP3626262A1 (en) 2020-03-25
IL256076A (en) 2018-01-31
PL3310379T3 (pl) 2020-03-31
HUE046631T2 (hu) 2020-03-30
AU2016278588B2 (en) 2022-03-31
PL3626262T3 (pl) 2025-02-17
CA2989247A1 (en) 2016-12-22
ES2760699T3 (es) 2020-05-14
ES2994561T3 (en) 2025-01-27
HK1252435A1 (en) 2019-05-24
LT3310379T (lt) 2019-12-27
KR20250024816A (ko) 2025-02-19
RU2018101722A3 (cg-RX-API-DMAC7.html) 2019-12-10
RU2018101722A (ru) 2019-07-18
US20180250345A1 (en) 2018-09-06
KR20180037948A (ko) 2018-04-13
WO2016202459A1 (en) 2016-12-22
US10905752B2 (en) 2021-02-02
EP3310379A1 (en) 2018-04-25
SI3310379T1 (sl) 2020-02-28
AU2016278588A1 (en) 2017-12-21
JP6947649B2 (ja) 2021-10-13
EP3626262C0 (en) 2024-10-23
JP2018517419A (ja) 2018-07-05
DK3310379T3 (da) 2019-12-16
EP3310379B1 (en) 2019-11-06
CN107995868B (zh) 2021-07-13
BR112017027378A2 (pt) 2018-08-28
MX2017016183A (es) 2018-06-19
CA2989247C (en) 2023-10-17

Similar Documents

Publication Publication Date Title
IL304084B1 (en) Gene healing
ZA201904717B (en) Therapeutic hpv18 vaccines
IL260030B2 (en) Neoepitope therapeutic vaccine against cancer
IL259017A (en) Cancer cure is intended
IL256634A (en) Therapeutic oligonucleotides
PL3553087T3 (pl) Terapia celowana nowotworu złośliwego płuc
ZA201703055B (en) Therapeutic hpv16 vaccines
ZA201708439B (en) Vegfr-2 targeting dna vaccine for combination therapy
PT3020430T (pt) Cânula para terapia de implantação de sutura catgut
GB201407322D0 (en) Gene therapy
ZA201808121B (en) Therapeutic hpv vaccine combinations
IL255853B (en) Nano-particles for use as a therapeutic vaccine
IL266237A (en) Tolerogenic DNA composition
IL265684A (en) dna vaccine targeting wt1 for combination therapy
PT3162378T (pt) Sistema de vacinação nasal para vacina contra a gripe
PL3329004T3 (pl) Terapeutyczne oligonukleotydy
HK40009852A (en) Wt1 targeting dna vaccine for combination therapy
EP3261673B8 (en) Combined vaccination/radioterapy for cancer treatment
GB201518917D0 (en) Vaccination
GB201503266D0 (en) Vaccination